Literature DB >> 29131101

Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study.

Nicholas J Goel1, Kalil G Abdullah, Shih-Shan Lang.   

Abstract

BACKGROUND/AIMS: Pediatric oligodendroglioma (pODG) is a rare primary brain tumor that remains poorly understood. Demographics, outcomes, and prognostic factors were analyzed in 346 pODG cases from the Surveillance, Epidemiology, and End Results database.
METHODS: Gender, race, age, tumor location, tumor size, tumor grade, extent of resection, and use of radiotherapy were evaluated with respect to overall survival (OS) by univariate and multivariate analysis. These factors were assessed in the pediatric cohort and 5,753 adult oligodendroglioma cases for comparison.
RESULTS: The mean OS in pODG was 199.6 months. Five- and 10-year survival rates were 85 and 81%. pODG arose less frequently in the frontal lobe than adult tumors (53 vs. 22%) but was more common in the temporal lobe (32 vs. 18%) and extracortical regions (19 vs. 5%, p < 0.0001). pODG presented with smaller size (55 vs. 24%, p < 0.0001) and lower grade (72 vs. 54%, p < 0.0001) than adult tumors. Tumor location, size, grade, use of radiotherapy, and extent of resection were significant prognostic factors. Size and grade were much stronger prognostic factors in children than adults. While children with oligodendroglioma survive much longer than adults on the whole, there was no difference in outcome between children with high-grade tumors and adults with high-grade tumors.
CONCLUSION: pODG differs significantly from adult oligodendroglioma along a number of demographic and tumor factors at a population level, and key prognostic factors influence survival differently in pODG than in adult disease.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Pediatric cancer; Pediatric oligodendroglioma; Surveillance, Epidemiology, and End Results database

Mesh:

Year:  2017        PMID: 29131101     DOI: 10.1159/000481458

Source DB:  PubMed          Journal:  Pediatr Neurosurg        ISSN: 1016-2291            Impact factor:   1.162


  5 in total

1.  Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.

Authors:  Gabrielle Truitt; Haley Gittleman; Rebecca Leece; Quinn T Ostrom; Carol Kruchko; Terri S Armstrong; Mark R Gilbert; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2019-06-17       Impact factor: 4.130

2.  The Misclassification of Diffuse Gliomas: Rates and Outcomes.

Authors:  J Bryan Iorgulescu; Matthew Torre; Maya Harary; Timothy R Smith; Ayal A Aizer; David A Reardon; Jill S Barnholtz-Sloan; Arie Perry
Journal:  Clin Cancer Res       Date:  2019-01-11       Impact factor: 12.531

Review 3.  Racial and ethnic disparities among children with primary central nervous system tumors in the US.

Authors:  Edwin Nieblas-Bedolla; Briana Christophers; John R Williams; Alexandra Power-Hays; Nathalia Jimenez; Analiz Rodriguez
Journal:  J Neurooncol       Date:  2021-03-28       Impact factor: 4.130

Review 4.  Epigenomics and immunotherapeutic advances in pediatric brain tumors.

Authors:  Malak Abedalthagafi; Nahla Mobark; May Al-Rashed; Musa AlHarbi
Journal:  NPJ Precis Oncol       Date:  2021-04-30

5.  Prognosis of Oligodendroglioma Patients Stratified by Age: A SEER Population-Based Analysis.

Authors:  Kai Jin; Shu-Yuan Zhang; Li-Wen Li; Yang-Fan Zou; Bin Wu; Liang Xia; Cai-Xing Sun
Journal:  Int J Gen Med       Date:  2021-12-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.